Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
This randomized, double-blind, placebo-controlled, multi-center study investigated the clinical efficacy of two probiotic strains on abdominal pain severity and symptomology in irritable bowel syndrome (IBS). Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, Lactobacillus acidophilus DDS-1 (1 × 1010 CFU/day) or Bifidobacterium animalis subsp. lactis UABla-12 (1 × 1010 CFU/day) over six weeks. The primary outcome was the change in Abdominal Pain Severity - Numeric Rating Scale (APS-NRS). Over the intervention period, APS-NRS was significantly improved in both probiotic groups vs. placebo in absolute terms (DDS-1: −2.59 ± 2.07, p = 0.001; UABla-12: −1.56 ± 1.83, p = 0.001) and in percentage of significant responders (DDS-1: 52.3%, p < 0.001); UABla-12 (28.2%, p = 0.031). Significant amelioration vs. placebo was observed in IBS Symptom Severity Scale (IBS-SSS) scores for L. acidophilus DDS-1 (−133.4 ± 95.19, p < 0.001) and B. lactis UABla-12 (−104.5 ± 96.08, p < 0.001) groups, including sub-scores related to abdominal pain, abdominal distension, bowel habits and quality of life. Additionally, a significant normalization was observed in stool consistency in both probiotic groups over time and as compared to placebo. In conclusion, L. acidophilus DDS-1 and B. lactis UABla-12 improved abdominal pain and symptom severity scores with a corresponding normalization of bowel habits in adults with IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
(1988) · Cited by 4,111
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 8×
“IBS symptom severity was assessed via the IBS Symptom Severity Scale (IBS-SSS) [23].”
MethodInfluentialActivation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833 · cited 1×
“There is evidence of an activation of the intestinal immune system in IBS resulting in inflammation, including augmented mucosal intraepithelial lymphocytes and mast cells [42,43].”
BackgroundLactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793 · cited 1×
“acidophilus has been shown to normalize visceral pain responses via induced expression of opioid and cannabinoid receptors in the gut [45].”
BackgroundSelf-citationPatrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761 · cited 1×
“IBS-related quality of life (QoL) was assessed via the IBS-QoL, a 34-item questionnaire with each item rated on a 5-point scale (range: 34–170), with increasing scores indicating deteriorating quality of life [25].”
MethodLiang, P., Liu, S., Xu, F., Jiang, S., Yan, J., He, Q., Liu, W., Lin, C., Zheng, F., Wang, X., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00001 · Cited by 669
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645 · cited 2×
“controlled trials with a dichotomous outcome enrolling a total of 4403 participants [7,11].”
BackgroundFord, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619 · cited 1×
“controlled trials with a dichotomous outcome enrolling a total of 4403 participants [7,11].”
BackgroundPathophysiology of irritable bowel syndrome
Holtmann, G. J., Ford, A. C., & Talley, N. J. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30023-1 · Cited by 590 · cited 1×
“Irritable bowel syndrome (IBS), a functional disorder of the gastrointestinal tract, is characterized by chronic or recurrent abdominal pain and altered bowel habits [1].”
BackgroundRome criteria and a diagnostic approach to irritable bowel syndrome
Lacy, B., & Patel, N. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6110099 · Cited by 575
Blake, M. R., Raker, J. M., & Whelan, K. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13746 · Cited by 495 · cited 1×
“Stool consistency was assessed via the Bristol Stool Scale (BSS), a validated ordinal scale of stool types [24] ranging from 1 through 7, with types 1–2 and 6–7, in conjunction with other symptoms, indicative of constipation and diarrhea, respectively.”
MethodImpact of psychological stress on irritable bowel syndrome
Qin, H.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14126 · Cited by 398
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum
Guilarte, M., Santos, J., de Torres, I., Alonso, C., Vicario, M., Ramos, L., Martinez, C., Casellas, F., Saperas, E., & Malagelada, J. R. (2007) · Gut · doi:10.1136/gut.2006.100594 · Cited by 385 · cited 1×
“There is evidence of an activation of the intestinal immune system in IBS resulting in inflammation, including augmented mucosal intraepithelial lymphocytes and mast cells [42,43].”
BackgroundDidari, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i10.3072 · Cited by 356
The Intestinal Microenvironment and Functional Gastrointestinal Disorders
Barbara, G., Feinle-Bisset, C., Ghoshal, U. C., Santos, J., Vanner, S. J., Vergnolle, N., Zoetendal, E. G., & Quigley, E. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.028 · Cited by 335 · cited 1×
“Mechanisms include visceral hypersensitivity, altered bowel motility, abnormal epithelial barrier or intestinal permeability, immune activation, neurotransmitter imbalance, infection and dysbiosis of the microbiota [2,3].”
BackgroundChong, P. P., Chin, V. K., Looi, C. Y., Wong, W. F., Madhavan, P., & Yong, V. C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01136 · Cited by 328 · cited 1×
“Multiple reports have linked IBS pathogenesis to dysbiosis of the microbiota [38,39], including low levels of Lactobacillus and Bifidobacterium [40], which could otherwise help inhibit binding of pathogens and reinforce defenses of the mucosal barrier.”
BackgroundGut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320 · cited 2×
“Multiple reports have linked IBS pathogenesis to dysbiosis of the microbiota [38,39], including low levels of Lactobacillus and Bifidobacterium [40], which could otherwise help inhibit binding of pathogens and reinforce defenses of the mucosal barrier.”
BackgroundUpdate on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice
Simren, M., Palsson, O. S., & Whitehead, W. E. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0554-0 · Cited by 255 · cited 1×
“The Rome Team Working Group has supported the concept that the intestinal microbiota is perturbed in IBS [41].”
BackgroundMeta‐analysis: factors affecting placebo response rate in the irritable bowel syndrome
Ford, A. C., & Moayyedi, P. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04328.x · Cited by 226 · cited 1×
“Placebo response is significant in IBS studies and has been demonstrated to be highest in trials with a one- to four-week intervention period [30].”
BackgroundDhakan, D. B., Maji, A., Sharma, A. K., Saxena, R., Pulikkan, J., Grace, T., Gomez, A., Scaria, J., Amato, K. R., & Sharma, V. K. (2019) · GigaScience · doi:10.1093/gigascience/giz004 · Cited by 216
Ghoshal, U. C., Abraham, P., Bhatt, C. B., Choudhuri, G., Bhatia, S. J., Shenoy, K. T., Banka, N. H., Bose, K. S. C., Bohidar, N. P., Chakravartty, K., et al. (2008) · PubMed · Cited by 193
Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X., & Li, Y. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0470-z · Cited by 181 · cited 2×
“An intervention period of six weeks was assessed for the primary outcome, as it is consistent with the four- to eight-week probiotic IBS study durations widely reported in the literature [9].”
ResultRingel-Kulka, T., Palsson, O. S., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., & Ringel, Y. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31820ca4d6 · Cited by 174 · cited 1×
“Similarly, the species has been shown to modulate μ-opioid receptor expression and activity, which has been suggested as a mechanism for the reduction of bloating in adults with functional abdominal pain [46,47].”
BackgroundSelf-citationResponder analyses and the assessment of a clinically relevant treatment effect
Snapinn, S. M., & Jiang, Q. (2007) · Trials · doi:10.1186/1745-6215-8-31 · Cited by 173
Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review
Dale, H. F., Rasmussen, S. H., Asiller, Ö. Ö., & Lied, G. A. (2019) · Nutrients · doi:10.3390/nu11092048 · Cited by 166 · cited 1×
“Mechanisms include visceral hypersensitivity, altered bowel motility, abnormal epithelial barrier or intestinal permeability, immune activation, neurotransmitter imbalance, infection and dysbiosis of the microbiota [2,3].”
BackgroundSpiller, R. C. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00086-8 · Cited by 164 · cited 1×
“An initial increase in placebo response has been reported before stabilizing over two to five weeks and decreasing after 12 weeks [31,32].”
BackgroundGerasimov, S. V., Vasjuta, V. V., Myhovych, O. O., & Bondarchuk, L. I. (2010) · American Journal of Clinical Dermatology · doi:10.2165/11531420-000000000-00000 · Cited by 161
Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy.
(2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8807 · Cited by 132 · cited 3×
“Multiple reports have linked IBS pathogenesis to dysbiosis of the microbiota [38,39], including low levels of Lactobacillus and Bifidobacterium [40], which could otherwise help inhibit binding of pathogens and reinforce defenses of the mucosal barrier.”
BackgroundDorn, S. D., Kaptchuk, T. J., Park, J. B., Nguyen, L. T., Canenguez, K., Nam, B. H., Woods, K. B., Conboy, L. A., Stason, W. B., & Lembo, A. J. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00937.x · Cited by 119 · cited 1×
“Alternatively, other reviews report a higher placebo response associated with longer treatment duration and a greater number of study visits [34].”
BackgroundSPIEGEL, B., BOLUS, R., HARRIS, L. A., LUCAK, S., NALIBOFF, B., ESRAILIAN, E., CHEY, W. D., LEMBO, A., KARSAN, H., TILLISCH, K., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04144.x · Cited by 112 · cited 5×
“Unlike most symptoms, such as altered bowel habits or bloating, abdominal pain has been shown to independently drive health-related quality of life decline in IBS and is the principal driver of patient-reported symptom severity [21,22].”
InfluentialGuidance on the scientific requirements for health claims related to gut and immune function
EFSA Panel on Dietetic Products, N. A. A. (. (2011) · EFSA Journal · doi:10.2903/j.efsa.2011.1984 · Cited by 99
Vemuri, R., Gundamaraju, R., Shinde, T., Perera, A. P., Basheer, W., Southam, B., Gondalia, S. V., Karpe, A. V., Beale, D. J., Tristram, S., et al. (2019) · Nutrients · doi:10.3390/nu11061297 · Cited by 82 · cited 2×
“acidophilus DDS-1 has exhibited immunomodulatory capacity in vitro [16], while both modulating the microbiota and downregulating the inflammatory profile in pre-clinical models [17,18].”
BackgroundSelf-citationPakdaman, M. N., Udani, J. K., Molina, J. P., & Shahani, M. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0172-y · Cited by 82 · cited 2×
“lactis UABla-12, has previously been shown to normalize bowel habits in functional constipation [12], provide abdominal symptom relief in lactose intolerance [13] and support immune specific outcomes [14,15] in randomized controlled trials.”
BackgroundMeasuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials
Spiegel, B. M. R., Bolus, R., Agarwal, N., Sayuk, G., Harris, L. A., Lucak, S., Esrailian, E., Chey, W. D., Lembo, A., Karsan, H., et al. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04464.x · Cited by 80 · cited 1×
“Unlike most symptoms, such as altered bowel habits or bloating, abdominal pain has been shown to independently drive health-related quality of life decline in IBS and is the principal driver of patient-reported symptom severity [21,22].”
BackgroundVemuri, R., Shinde, T., Gundamaraju, R., Gondalia, S. V., Karpe, A. V., Beale, D. J., Martoni, C. J., & Eri, R. (2018) · Nutrients · doi:10.3390/nu10091255 · Cited by 79 · cited 2×
“acidophilus DDS-1 has exhibited immunomodulatory capacity in vitro [16], while both modulating the microbiota and downregulating the inflammatory profile in pre-clinical models [17,18].”
BackgroundSelf-citationRanuh, R., Fardah Athiyyah, A., Darma, A., Prasetyo Risky, V., Riawan, W., S. Surono, I., & Marto Sudarmo, S. (2019) · Iranian Journal of Microbiology · doi:10.18502/ijm.v11i2.1077 · Cited by 74 · cited 1×
“More recently, Lactobacillus was shown to upregulate expression of both serotonin transporter and intestinal serotonin levels [48], which further suggests a potential gut-brain role.”
BackgroundRingel‐Kulka, T., Goldsmith, J. R., Carroll, I. M., Barros, S. P., Palsson, O., Jobin, C., & Ringel, Y. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12800 · Cited by 72
Rahman, M. M., Mahadeva, S., & Ghoshal, U. C. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i37.6788 · Cited by 69 · cited 2×
“The lack of an obvious female predominance among IBS subjects in this study is in agreement with other Asian reports, and in contrast to a 2–3-fold greater prevalence among females in Western populations [27,28].”
BackgroundResultMartoni, C. J., Evans, M., Chow, C. T., Chan, L. S., & Leyer, G. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12797 · Cited by 67 · cited 3×
“lactis UABla-12, has previously been shown to normalize bowel habits in functional constipation [12], provide abdominal symptom relief in lactose intolerance [13] and support immune specific outcomes [14,15] in randomized controlled trials.”
BackgroundSelf-citationStudy design considerations for irritable bowel syndrome clinical trials.
Miller, L. E. (2014) · PubMed Central · Cited by 64
Vemuri, R., Shinde, T., Shastri, M. D., Perera, A. P., Tristram, S., Martoni, C. J., Gundamaraju, R., Ahuja, K. D. K., Ball, M., & Eri, R. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.25004 · Cited by 47 · cited 1×
“acidophilus DDS-1 has exhibited immunomodulatory capacity in vitro [16], while both modulating the microbiota and downregulating the inflammatory profile in pre-clinical models [17,18].”
BackgroundSelf-citationProbiotics in irritable bowel syndrome: Where are we?
Barbara, G., Cremon, C., & Azpiroz, F. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13513 · Cited by 45
Bacterial modulation of visceral sensation: mediators and mechanisms
Lomax, A. E., Pradhananga, S., Sessenwein, J. L., & O’Malley, D. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00052.2019 · Cited by 38
Gerasimov, S. V., Ivantsiv, V. A., Bobryk, L. M., Tsitsura, O., Dedyshin, L. P., Guta, N., & Yandyo, B. V. (2015) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2015.171 · Cited by 37 · cited 1×
“lactis UABla-12, has previously been shown to normalize bowel habits in functional constipation [12], provide abdominal symptom relief in lactose intolerance [13] and support immune specific outcomes [14,15] in randomized controlled trials.”
BackgroundSpiegel, B. M. R., Bolus, R., Harris, L. A., Lucak, S., Chey, W. D., Sayuk, G., Esrailian, E., Lembo, A., Karsan, H., Tillisch, K., et al. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04443.x · Cited by 35 · cited 1×
“The current study focused on abdominal pain as the primary outcome as it is a defining characteristic of IBS and a driver of healthcare resource utilization [20].”
BackgroundEFSA Panel on Nutrition, N. F. A. F. A. (. N. P., Turck, D., Castenmiller, J., De Henauw, S., Hirsch‐Ernst, K. I., Kearney, J., Knutsen, H. K., Maciuk, A., Mangelsdorf, I., McArdle, H. J., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5434 · Cited by 19
Study design issues in irritable bowel syndrome
Mangel, A. W. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01816.x · Cited by 8 · cited 1×
“An initial increase in placebo response has been reported before stabilizing over two to five weeks and decreasing after 12 weeks [31,32].”
Background
Research works printed but not linked: 1
- Nagala, 2011, Clinical Case Study—Multispecies probiotic supplement minimizes symptoms of irritable bowel syndrome, US Gastroenterol. Hepatol. Rev., 7, 1
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Rastogi, S., & Singh, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1042189 · Cited by 326
Lactobacillus and intestinal diseases: Mechanisms of action and clinical applications
Huang, R., Wu, F., Zhou, Q., Wei, W., Yue, J., Xiao, B., & Luo, Z. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127019 · Cited by 250
Abouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 238
“Those who supplemented with L. acidophilus DDS-1 and B. lactis UABla-12 also witnessed a normalization of stool patterns and experienced enhanced relief from abdominal pain throughout the intervention period [94].”
BackgroundWorld Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209
Metadata
- Authors
- Martoni, C. J., Srivastava, S., & Leyer, G. J.
- Affiliations
- UAS Laboratories LLC, 4375 Duraform Lane, Windsor, WI 53598, USA
- Vedic Lifesciences (India) (IN)
- Corresponding author
- Leyer, Gregory J.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-01-30
- Volume
- 12
- Issue
- 2
- Pages
- 363
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC7071206
- OpenAlex
- W3004290421
- Cited by
- 123
- References
- 50
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 25 · 2023: 22 · 2022: 25 · 2021: 8 · 2020: 6
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, probiotics, abdominal pain, symptom severity, abdominal distension, bowel habits, stool consistency, quality of life, Rome IV criteria
- MeSH terms
- Bifidobacterium animalis, Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Lactobacillus acidophilus, Male, Middle Aged, Severity of Illness Index, Abdominal Pain, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.